<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230122</url>
  </required_header>
  <id_info>
    <org_study_id>17458</org_study_id>
    <secondary_id>J2F-MC-OHAA</secondary_id>
    <nct_id>NCT04230122</nct_id>
  </id_info>
  <brief_title>A Study of LY3478006 in Healthy Participants</brief_title>
  <official_title>A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3478006 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is
      when given by injection into a vein or just under the skin to healthy participants. Blood
      tests will be done to check how much LY3478006 is in the bloodstream and how long the body
      takes to get rid of it. For each participant, the study will last up to about 16 weeks,
      including screening.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol stopping criteria (safety) were met.
  </why_stopped>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Actual">June 4, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3478006</measure>
    <time_frame>Predose on Day 1 through Day 85</time_frame>
    <description>PK: Cmax of LY3478006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC0-∞) of LY3478006</measure>
    <time_frame>Predose on Day 1 through Day 85</time_frame>
    <description>PK: AUC0-∞ of LY3478006</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3478006 - Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3478006 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3478006 - Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3478006 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3478006 - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3478006 - Intravenous (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3478006 - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3478006 - Subcutaneous (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy male or female Japanese or non-Japanese participants, as
             determined by medical history and physical examination

          -  Women not of childbearing potential

          -  Are aged 18 to 55 years (20 to 55 years for Japanese participants), inclusive, at
             screening

        Exclusion Criteria:

          -  Have clinically significant abnormal electrocardiogram (ECG) results

          -  Have persistent abnormal blood pressure or pulse rate, as determined by the
             investigator

          -  Have evidence of orthostatic hypotension, defined as a decrease in systolic or
             diastolic blood pressure greater than or equal to (≥)20 millimeters of mercury (mmHg)
             or ≥10 mmHg, respectively

          -  Have significant history or presence of cardiovascular, respiratory, hepatic,
             ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or
             psychiatric disorders

          -  Have a history or presence of mononeuropathy, polyneuropathy, or autonomic neuropathy

          -  Have significant allergies to humanized monoclonal antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

